Search results
BMS reports four-year data from psoriasis treatment extension trial
Clinical Trials Arena via Yahoo Finance· 4 days agoThe study followed the Phase III POETYK PSO-1 and POETYK PSO-2...remained consistent over the four...
Nail Psoriasis
Health via Yahoo News· 4 days agoPeople with moderate to severe forms of both conditions may live a few years less on average. Early diagnosis, treatment, and management of your...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. -...
Benzinga· 11 hours agoALVO, today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid ...
InnoCare Pharma concludes subject enrolment Phase II psoriasis trial
Clinical Trials Arena via Yahoo Finance· 5 days agoInnoCare Pharma has announced the completion of subject enrolment in the Phase II clinical trial of...
Ultravate side effects: What they are and how to manage them
Healthline· 1 day agoUltravate (halobetasol propionate) is a prescription drug that’s used to treat plaque psoriasis. Ultravate can cause side effects that range from mild to ...
State board targets six prescription drugs to review for affordability for Marylanders
Maryland Matters via Yahoo News· 11 hours agoThe board will seek public comments, additional information and data over the next 60 days to...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 23 hours ago...20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative colitisa (UC) receiving subcutaneous (SC) TREMFYA® (guselkumab) 200 mg...
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...
The Parsons Sun· 4 days ago- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)
AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research Forecasts
ETF DAILY NEWS· 5 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Zacks Research lifted their Q2 2024 earnings estimates for shares of AbbVie in a research report issued to clients and investors on Tuesday ...
Why Is My Scalp Flaky? Exploring The Causes Of Dandruff And How It’s Treated
IFLScience· 3 days agoAccording to the American Academy of Dermatology, dandruff itself may be considered a mild form of a...